Reporters.io
Pharmaceutical Executive Editorial Staff
Pharmaceutical Executive
Profile
Contacts
Recent Articles on Subject
1
Pharmaceutical Executive Editorial Staff
Pharmaceutical Executive
Pharma Executive Magazine.
London & New Jersey
Pharmaceuticals
Healthcare
FDA Issues Complete Response Letter to Astellas for Zolbetuximab BLA for GEJ Adenocarcinoma
- 12 months ago
FDA Grants Priority Review to Pfizer and Genmab's Tivdak for Cervical Cancer Treatment
- 12 months ago
ProfoundBio's Rinatabart Sesutecan Granted FDA Fast Track Designation for Ovarian Cancer
- 12 months ago
Novartis Announces Positive Findings for Scemblix in Newly Diagnosed Chronic Myeloid Leukemia
- 12 months ago
Zelix Pharmaceuticals Files BLA for PET Imaging Agent for Renal Cell Carcinoma
- 12 months ago
Pivotal Phase III Trials to Evaluate Four Promising Agents in Merck's Oncology, Hematology Pipeline
- 12 months ago
Setting the Stage for Specialty Drugs in 2024: Q&A with Tina Fresta, Strategic Solutions Senior Manager at epocrates
- 12 months ago
CVS to Remove Humira From Some Reimbursement Lists in Favor of Biosimilar Options
- 12 months ago
Eli Lilly Launches Telehealth Platform to Sell Certain Drugs Directly to Consumers
- 12 months ago
FDA Grants Fast Track, Breakthrough Designations to CG Oncology Inc’s Cretostimogene Grenadenorepvec
- 12 months ago
Invivyd Seeks EUA for Monoclonal Antibody Designed to Prevent COVID-19 in Immunocompromised Individuals
- 12 months ago
FDA Fast Tracks Candel Therapeutics' Novel Treatment for Pancreatic Ductal Adenocarcinoma
- 12 months ago
AstraZeneca Bolsters Cellular Therapy Pipeline With Acquisition of Gracell Biotechnologies
- 12 months ago
FDA Grants Priority Review to Genentech's sBLA for Xolair to Treat Food Allergies
- about 1 year ago
FDA Accepts Biologics License Application for CSL Behring’s Garadacimab for Hereditary Angioedema
- about 1 year ago
FDA Approves Filsuvez for Epidermolysis Bullosa
- about 1 year ago
Merck's 21-Valent Pneumococcal Conjugate Vaccine Granted FDA Priority Review
- about 1 year ago
FDA Approves Expanded Indication for LEO Pharma's Adbry for Pediatric Patients With Atopic Dermatitis
- about 1 year ago
Moderna's Novel mRNA Vaccine Shows Significant Efficacy Against RSV
- about 1 year ago
GSK's Jemperli Plus Zejula Produces Significant Survival Improvement in Endometrial Cancer
- about 1 year ago
Arcutis Biotherapeutics, Inc’s Zoryve Gets FDA Approval for Seborrheic Dermatitis
- about 1 year ago
FDA Approves Padcev/Keytruda Combo for Locally Advanced, Metastatic Urothelial Cancer
- about 1 year ago
Erasca’s Naporafenib Gets FDA Fast Track Designation for Metastatic Melanoma
- about 1 year ago
Moderna and Merck's Novel Cancer Vaccine, Keytruda Combo Cuts Risk of Skin Cancer Death, Recurrence by Half
- about 1 year ago
CDC Raises Urgent Alert for Low Vaccination Coverage for COVID-19, Influenza, RSV
- about 1 year ago
FDA Approves Merck's Welireg for Advanced Renal Cell Carcinoma
- about 1 year ago
FDA Approves First Treatment Indicated to Lower Risk of Relapse in Pediatric Patients With High-Risk Neuroblastoma
- about 1 year ago
Pfizer Clears Final Regulatory Hurdles to Acquire Seagen Inc
- about 1 year ago
MAPS Seeks Approval of First Psychedelic-Assisted Therapy for PTSD
- about 1 year ago
AstraZeneca Strengthens Respiratory Illness Pipeline With Acquisition of Icosavax
- about 1 year ago
Bristol Myers Squibb to Pay Up to $8.4 Billion to Codevelop Antibody-Drug Conjugate With SystImmune
- about 1 year ago
Merck and Moderna to Launch Trial of mRNA-4157 Plus Keytruda in Non-Small Cell Lung Cancer
- about 1 year ago
FDA Expands Indication of Cresemba for Use in Children With Invasive Aspergillosis, Invasive Mucormycosis
- about 1 year ago
FDA Approves Two Landmark Cell-Based Gene Therapies for Sickle Cell Disease
- about 1 year ago
Prevalence of Eight Chronic Health Conditions Reach Unprecedented Levels in US
- about 1 year ago
Teva's Ajovy Shows Similar Efficacy Reducing Migraine Attacks in Patients With Obesity
- about 1 year ago
Merck Halts Phase 3 Trial of Keytruda Combination for Non-Small Cell Lung Cancer
- about 1 year ago
Merck Halts Phase III Trial of Keytruda Combination for Non-Small Cell Lung Cancer
- about 1 year ago
CVS Becomes Latest PBM to Overhaul Drug Pricing Formula
- about 1 year ago
FDA Approves Novartis’ Fabhalta for Paroxysmal Nocturnal Hemoglobinuria
- about 1 year ago
Eli Lilly Announces Availability of Obesity Drug Zepbound at US Pharmacies
- about 1 year ago
FDA Grants Breakthrough Designation to Johnson & Johnson’s Novel Treatment for HR-NMIBC
- about 1 year ago
FDA Grants Priority Review to Bristol Myers Squibb's Opdivo Combination for Urothelial Carcinoma
- about 1 year ago
Roche Bolsters Obesity, Diabetes R&D Portfolio With Acquisition of Carmot Therapeutics
- about 1 year ago
FDA Approves Lilly's Jaypirca for Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- about 1 year ago
FDA Grants Priority Review to Keytruda Plus Padcev for Urothelial Carcinoma
- about 1 year ago
FDA Fast Tracks eFFECTOR Therapeutics' Zotatifin Combo for ER+/HER2– Breast Cancer
- about 1 year ago
AbbVie to Acquire ImmunoGen With its Platinum-Resistant Ovarian Cancer Drug Elahere
- about 1 year ago
FDA Accepts Arcutis Biotherapeutics' sNDA for Roflumilast Cream for Atopic Dermatitis
- about 1 year ago
FDA Issues Warning of Potential Adverse Events Associated With Antiseizure Drugs
- about 1 year ago